Elekta Medical, S.A.
$2.3K 1 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Oxford Gene Technology Inc
Oxford Gene Technology Inc reported $2,323.62 across General Payments, Research, and Ownership to 87 physicians and teaching hospitals across 87 transactions.
- $2.3K Below-median payer
- All-tracks total
- 87 Below-median volume
- Transactions
- 87 Below-median reach
- Recipients
- −$7.5K
- General Payments vs PY2023
Oxford Gene Technology Inc reported $2,323.62 across all CMS Open Payments tracks (General + Research + Ownership) to 87 physicians and teaching hospitals in Program Year 2024 - ranking #1786 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $2,323.62, averaging $26.71 per recipient.
How Oxford Gene Technology Inc's $2.3K all-tracks total breaks down
Oxford Gene Technology Inc's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
14/100
Total payments
F
10/100
Transaction volume
F
11/100
Physician reach
F
11/100
Payment type diversity
F
23/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer oxford-gene-technology-inc Oxford Gene Technology Inc
$2.3K · #1786/1,925 · 0.0% industry · PY2024
- TOT $2.3K
- RANK #1786
- SHARE 0.0%
- TXN 87
- RCP 87
- CAT 2
- GEN $2.3K
- ΔGEN −$7.5K
- TOP1 13.3%
- PY 2024
Volume peers
Nearest volume peer: Elekta Medical, S.A. ($2.3K)
Oxford Gene Technology Inc sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Oxford Gene Technology Inc's CMS-reported General Payments decreased by $7.5K (−76.5%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: OXFORD GENE TECHNOLOGY INCPY2023: OXFORD GENE TECHNOLOGY INCPY2024: OXFORD GENE TECHNOLOGY INC. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $9,867.06
- PY2024
- $2,323.62
What the Data Shows for Oxford Gene Technology Inc
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Oxford Gene Technology Inc, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
85 transactions worth $1.9K make "Food and Beverage" the top general-payment category in the 2-category breakdown below, 82.8% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Oxford Gene Technology Inc made 2 types of general payments. "Food and Beverage" is the largest category at $1.9K, 82.8% of General Payments.
How Oxford Gene Technology Inc divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Food and Beverage | $1.9K | 85 | 82.8% |
| Honoraria | $400.00 | 2 | 17.2% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $1,252.87 (53.9%) of $2,323.62 in this company's General Payments records across 16 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Oxford Gene Technology Inc
The five named recipients with the highest reported General Payments from this company
- 1
Memorial Regional Hospital
$307.99 across 19 reported transactions
- 2
Moffitt Cancer Center
$255.41 across 12 reported transactions
- 3
Hartford Hospital
$242.07 across 6 reported transactions
- 4
Eric Vail
$236.30 across 2 reported transactions
- 5
Texas Childrens Hospital
$211.10 across 7 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Oxford Gene Technology Inc ranks #1786 of 1,925 by total payments (bottom 7% by spend) but is notably more concentrated than that alone would suggest -- #1,080 of 1,838 by HHI (bottom 41% least concentrated). Its payments land on an unusually narrow set of recipients for its spend size.
View all 12 companies in this HHI neighborhood as a list
- Asahi Intecc USA, Inc. : $443.1K total payments, HHI 885
- Clariance, Inc. : $125.5K total payments, HHI 882
- Sirona Dental Systems GmbH : $108.6K total payments, HHI 881
- GT Medical Technologies, Inc : $345.6K total payments, HHI 879
- Royal Biologics, Inc. : $415.5K total payments, HHI 879
- Labcorp Holdings Inc. : $1.2K total payments, HHI 868
- Oxford Gene Technology Inc (this company) : $2.3K total payments, HHI 865
- FX Shoulder Solutions, Inc : $525.5K total payments, HHI 863
- World Class Technology Corporation : $124.1K total payments, HHI 863
- Reflow Medical Inc : $126.3K total payments, HHI 862
- Clinician's Choice Dental Products Inc. : $76.0K total payments, HHI 859
- Arineta, Inc : $1.9K total payments, HHI 859
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Oxford Gene Technology Inc's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Oxford Gene Technology Inc.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Oxford Gene Technology Inc.
Showing 6 of 1,924 companies with CMS-reported payment data.
Ortho Systems
$2.4K 14 recipients
Compare payment profiles
Dymicron
$2.3K 1 recipients
Compare payment profiles
CPM Medical Consultants, LLC
$2.4K 25 recipients
Compare payment profiles
Levita Magnetics International Corp.
$2.4K 60 recipients
Compare payment profiles
Elekta Solutions AB
$2.4K 1 recipients
Compare payment profiles
Put this to use
Oxford Gene Technology Inc ranks #1786 of 1,925 by all-tracks total payments, led by "Food and Beverage".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Food and Beverage" spend across every manufacturer, not just Oxford Gene Technology Inc. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.